Bianhong Wang
Overview
Explore the profile of Bianhong Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang R, Xu Y, Wang B, Wang H, Wang M, Jing Y, et al.
Ann Hematol
. 2023 Nov;
103(1):61-71.
PMID: 37926751
Since HMAs were recommended for treatments in AML and MDS, we wondered whether HMAs could provide similar benefit to AML and intermediate/high-risk MDS under the direction of next-generation sequencing. Here...
2.
Zhou E, Yu F, Wang Y, Bi Y, Tuan H, Huang Y, et al.
Eur J Dermatol
. 2023 Aug;
33(3):270-279.
PMID: 37594335
Background: Xanthoma disseminatum (XD) is a rare form of non-Langerhans histiocytosis with extensive cutaneous involvement. There is a paucity of evidence-based recommendations for treatment decision-making. Previous case reports have established...
3.
Huang Y, Wang Y, Yu F, Mao X, Wang B, Li J, et al.
Front Immunol
. 2022 May;
13:894464.
PMID: 35514998
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy. Its clinical symptoms usually respond well to...
4.
Hu X, Wang B, Chen Q, Huang A, Fu W, Liu L, et al.
J Cancer
. 2021 Jul;
12(16):4912-4923.
PMID: 34234861
Intermediate risk acute myeloid leukemia (AML) comprises around 50% of AML patients and is featured with heterogeneous clinical outcomes. The study aimed to generate a prediction model to identify intermediate...
5.
Wang B, Guan W, Lv N, Li T, Yu F, Huang Y, et al.
Hematology
. 2021 May;
26(1):371-379.
PMID: 33971800
Objectives: The outcome of elderly acute myeloid leukemia (AML) patients is poor, which was traditionally attributed to patient- and leukemia-related factors. However, studies about the genetic features of these elderly...
6.
Liang Y, Zhou H, Yao Y, Deng A, Wang Z, Gao B, et al.
Oncotarget
. 2017 May;
8(28):45566-45576.
PMID: 28545017
Radiation enteropathy is a common complication in cancer patients following radiation therapy. Thus, there is a need for agents that can protect the intestinal epithelium against radiation. 12-O-tetradecanoylphorbol-13-acetate (TPA) has...
7.
Yan X, Xu N, Meng C, Wang B, Yuan J, Wang C, et al.
Am J Transl Res
. 2016 May;
8(2):419-32.
PMID: 27158336
The technology to reprogram human somatic cells to pluripotent state allows the generation of patient-specific induced pluripotent stem cells (iPSCs) and holds a great promise for regenerative medicine and autologous...
8.
Wang B, Liu Y, Hou G, Wang L, Lv N, Xu Y, et al.
Oncotarget
. 2016 Apr;
7(22):32065-78.
PMID: 27062340
Intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML cases, is highly heterogeneous. Although several mutations have been identified, the heterogeneity of AML is uncertain because...
9.
10.
Wang X, Wang B, Wang Y
Am J Orthod Dentofacial Orthop
. 2015 Dec;
148(6):974-81.
PMID: 26672703
Introduction: White spot lesions are an undesired side effect of fixed orthodontic treatment. The objective of this research was to develop an antibacterial resin-modified glass ionomer cement (RMGIC) containing nanoparticles...